



FY20 Full Year Results

Update on Essity Proposal

Sid Takla

CEO & Managing Director

Andrew Leyden

Chief Financial Officer

17 February 2021



Important Notice and Disclaimer



This presentation has been prepared by Asaleo Care Limited (ACN 154 461 300) (**Company**). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (together, the **Group**) and their activities current as at 16 February 2021 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. It has been prepared by the Company with due care but so far as applicable laws and regulatory requirements permit, the Group and its officers, employees and representatives provide no representation, warranty or assurance, express or implied, in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this presentation. This presentation is not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

Not an offer or financial product advice: The Company is not licensed to provide financial product advice. This presentation is not and should not be construed as, and does not contain or purport to contain, legal, tax, accounting or investment advice or an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly, securities in any member of the Group or any other financial products. This presentation is for information purposes only.

Financial data: All dollar values are in Australian dollars (\$) or A\$). Any financial data in this presentation is unaudited.

Effect of rounding: A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. Similarly, diagrams used in this presentation are illustrative only and may not necessarily be shown to scale.

Underlying financial information: As a result of non-recurring income and expenditure in FY20 and FY19, underlying financial information is included in this presentation.

Past performance: Any operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

Future performance: This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan", "project" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future financial performance, growth options, strategies and new products. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Recipients of this presentation are strongly cautioned not to place undue reliance on forward-looking statements.

Forward-looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry, or statements which may assume the success of the Group's business strategies, the success of which may not be realised within the period for which the forward-looking statement may have been prepared, or at all. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including but not limited to its accuracy, likelihood of achievement or reasonableness). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward-looking statements in this presentation speak only as of the date of this presentation. Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.

Non-IFRS terms: This presentation contains certain financial data that has not been prepared in accordance with a definition prescribed by Australian Accounting Standards or International Financial Reporting Standards, including the following measures: EBITDA, EBITDA margin, EBIT, maintenance capital expenditure, growth capital expenditure or performance improvement capital expenditure. Because these measures lack a prescribed definition, they may not be comparable to similarly titled measures presented by other companies, and nor should they be considered as an alternative to financial measures calculated in accordance with Australian Accounting Standards and International Financial Reporting Standards. Although the Company believes that these non-IFRS terms provide useful information to recipients in measuring the financial performance and the condition of the business, recipients are cautioned not to place undue reliance on such measures.



FY20 Highlights

Sid Takla

CEO & Managing Director



FY20 Headlines

Strong performance despite COVID-19 impacts; EBITDA ahead of guidance



REVENUE GROWTH

Continuing revenues
\$419.2m, up +2.3%



- Retail and B2B Healthcare collectively **up 6.7%**
- Market share growth in key retail categories
- Professional Hygiene down **only 4%** despite COVID-19 restrictions impacting “away-from-home” activity

SOLID PROFIT GROWTH

Underlying EBITDA
\$89.2m, up +6.3%



- EBITDA **up 6.3%** despite **11% increase** in brand investment
- Margin **growth 1.9pp**; favourable input costs, mix
- Continuing NPAT up 25.2%
- **No** COVID-19 related government **assistance**

STRONG, FLEXIBLE BALANCE SHEET

Net Debt
\$94.9m, down 31.9%



- Net debt **reduction \$44.4m**
- Leverage ratio **down to 1.21**
- Dividend declared 3 cps; **fully franked**
- Finance facilities **extended**

PORTFOLIO OPTIMISED

Exposure to higher
growth, higher margin
categories



- **Less exposure** to capital intensive, low margin consumer tissue
- **Exited** baby category NZ
- TOM Organic **acquisition completed** 29 January 2021

Category Growth FY20

Strong growth in key segments mitigated COVID-19 impacts



Feminine Care revenue **up 12%**

Retail Incontinence **up 10%**


Consumer Tissue NZ **up 3%;** branded **up 7%**

B2B Incontinence Healthcare **up 9%**

Professional Hygiene **down only 4%**

despite impact of COVID-19 restrictions on 'away from home' activity

Investment across key categories drove market share gains and revenue growth



Bubble size represents relative revenue contribution

Safety

Our first priority

COVID-19 response

- Strong culture of compliance
- No cases reported amongst team
- No disruption to production
- Working from home facilitated successfully
- Positive feedback from regulatory institutions on readiness and proactivity


Capital investment

- Invested \$2m of capital expenditure to strengthen protective safety measures

Safety performance

- TIFR and Severity at **lowest levels in many years** and trending down
- Closed and decommissioned NZ baby manufacturing site without injuries

Key Safety Metrics



LTIFR: Lost Time Injury Frequency Rate (lost time injuries per million hours worked)
TIFR: Total Injury Frequency Rate (lost time & medical injuries per million hours worked)
Severity Rate: Days lost per lost time injury (includes employees and contractors)

Sustainability

A year of great progress and more to come



INCLUSION + DIVERSITY

Launched inaugural **Reconciliation Action Plan** supporting Aboriginal and Torres Strait Islander Peoples



ENVIRONMENTAL IMPACT

Reduced total energy consumption by more than 50% since 2015



COMMUNITY ENGAGEMENT

Inducted to **Ronald McDonald House Charities Australia Supporter Hall of Fame** for long-standing support and partnership



PRODUCT STEWARDSHIP

Awarded government grant to explore end-of-life recycling options for used absorbent products



RESPONSIBLE SOURCING

Celebrated **10 years of Forest Stewardship Council (FSC®) Certification**



FY20 Financial Performance

Andrew Leyden
Chief Financial Officer



Income Statement

A solid result despite COVID-19



Revenue \$419.2m, **up 2.3%**; Retail **+6.2%**, B2B **-1.0%**

- Retail growth 6%; higher brand investment
- Strong performance in higher margin Feminine Care (12%) and Incontinence (10%) categories
- B2B down 1%
 - Incontinence Healthcare up 9%; new products, contract wins
 - Professional Hygiene down only 4%; despite COVID-19 restrictions impacting “away from home” demand

Margin expansion **up 2pp**

- Lower pulp costs, benefits from supply investments in NZ
- Lower imports pricing
- Partially offset by higher insurance, FX, Consumer Tissue Australia stranded costs

SM&A increase

- Brand investment **11% up**, Consumer Tissue Australia stranded costs, management incentives

Continuing EBITDA \$89.2m, **up 6.3%**, EPS 7.0 cps, **up 34.6%**

- EBIT up 4.9% (higher depreciation)
- Finance costs down on lower net debt
- Continuing NPAT up 34.0%

\$m	FY20	FY19	%
Revenue from continuing operations	419.2	409.7	2.3%
Cost of sales	(229.5)	(236.2)	(2.9%)
Distribution expenses	(42.2)	(37.0)	14.1%
Gross margin	147.5	136.5	8.1%
GM%	35%	33%	2pp
Sales, Marketing & Admin	(54.0)	(47.2)	14.4%
Other income/expenses	(4.3)	(5.4)	(20.3%)
EBITDA continuing	89.2	83.9	6.3%
Depreciation and amortisation	(26.6)	(24.2)	9.9%
EBIT	62.6	59.7	4.9%
Net finance costs	(8.0)	(11.9)	(32.8%)
Income tax expense	(15.6)	(14.0)	11.4%
Non-recurring	(0.8)	(3.2)	(75.0%)
NPAT continuing	38.2	30.5	25.2%
Statutory NPAT	32.3	22.1	46.2%
EPS (cents) continuing	7.0	5.2	34.6%

Reconciliation of Continuing to Statutory NPAT



NZ Baby \$11.3m

- Underlying trading loss
- Stock write off, inventory clearance costs
- Site makegood
- Redundancies
- Onerous lease

AU Consumer Tissue \$4.7m

- Distribution network restructuring VIC & QLD
- Final settlement costs

\$m	FY20	FY19
NPAT continuing operations	38.2	30.5
<u>Discontinued operations</u>		
NZ Baby	(11.3)	(2.8)
AU Consumer Tissue*	(4.7)	(4.5)
Income tax benefit	10.1	(1.1)
NPAT	32.3	22.1

* Australian Consumer Tissue sold 29 March 2019; costs relating to sale recognized in FY19 and FY20.

Retail

Higher brand investment and innovation driving market share growth




Retail revenue \$199.8m, up 6.2%

- Strong growth in key categories; Feminine Care 12%, Incontinence 10%, Consumer Tissue NZ 3% (branded 7%)
- Market share growth in key categories:
 - Brand investment up 18%
 - NPD; new Libra packaging, Tena Men and Tena Discreet
 - Rapid response to COVID-19 demand via local manufacturing
 - Exit of NZ private label tissue contracts to allow branded growth
- Benefit of panic buying in 1H reversed 2H

Retail EBITDA \$41.3m, up 11.3%

- Revenue growth in core categories
- Margin expansion; lower trade spending during COVID-19 restrictions, production benefits, lower pulp prices
- 18% increase in brand investment accommodated

\$m	FY20	FY19	%
Revenue	199.8	188.1	6.2%
EBITDA	41.3	37.1	11.3%
EBITDA %	20.7%	19.7%	1pp



Business to Business (B2B)

Strong growth in Incontinence Healthcare, resilience in Professional Hygiene




B2B revenue **\$219.4m**, down 1%

- Incontinence Healthcare revenue **up 8.8%**
 - Strong Tena demand
 - Organic growth and new contract wins
 - Government incentives driving higher level of “in-home” care
- Professional Hygiene **down 4.0%**
 - Robust result given impact of COVID-19 restrictions on “away from home” in commercial, hospitality and public facilities
 - Growth in some categories (soaps, sanitisers, towel)

B2B EBITDA **\$47.8m**, **up 2.1%**

- Margin expansion
 - Lower pulp and imported product prices
 - Cost savings in paper conversion from supply investments
 - Partially offset by higher insurance, FX and Australian Consumer Tissue stranded costs
- Higher SM&A
 - Consumer Tissue Australia stranded costs
 - Management incentives

\$m	FY20	FY19	%
Revenue	219.4	221.6	(1.0%)
EBITDA	47.8	46.8	2.1%
EBITDA %	21.8%	21.1%	0.7pp



Balance Sheet

Capacity to pay dividends and flexibility to invest in growth opportunities



Cash balance **up \$21.9m**

- Strong cash generation, improved working capital

Current assets **\$28.2m lower**

- Lower inventory, including clearance of baby stocks, delayed inbound orders (shipping)
- Significantly improved collections, timing of receipts

Current liabilities **\$4.5m higher**

- Lower trade payables (delayed inbound goods)
- Higher current lease liabilities
- Increase derivatives liability - mark to market FX contracts (stronger AUD, NZD)

Non-current liabilities **down \$25.3m**

- Debt paydown
- Lower lease liabilities (movement to current)

Dividend 3 cps declared; **fully franked**

Net debt **down \$44.4m** to \$94.9m

\$m	FY20	FY19
Cash	55.1	33.2
Current assets (exc. cash)	109.9	138.1
Non-current assets	308.1	309.7
Total assets	473.1	481.0
Current liabilities	95.0	90.5
Non-current liabilities	183.0	208.3
Total liabilities	278.0	298.8
Net assets	195.1	182.1
Cash	55.1	33.2
Debt	(150.0)	(172.5)
Net debt	(94.9)	(139.3)

Net Debt and Leverage

Major reset of net debt position FY19 and FY20



Net debt \$94.9m, **down \$44.4m**


- Lowest since listing

Comfortable debt and leverage position


Debt capacity \$250m, facilities **extended**

- Facility A (\$70m) extended to July 2023
- Facility B (\$40m) tenure unchanged
- Facility C (\$50m) extended to July 2024
- Just under \$100m undrawn
- \$55.1m cash

Net Debt + Leverage



Facilities



Cash Flow

Strong cash generation used to fund dividends and reduce debt



Operating \$87.1m

- Strong cash generation, improved working capital
- Tax payments \$2.0m
 - New Zealand and Fiji payments, offset by refund in Australia
- Net interest \$7.0m
 - Interest down on reduced debt


Investing \$19.5m

- Strategic and maintenance capex \$20.5m
 - production, IT investments, dispensers
- Proceeds from sale of baby assets \$1.0m

Financing \$45.3m

- Debt repayment \$22.5m
- Dividend \$10.9m, 2 cents per share, paid 1H20

Cash Movement FY19 to FY20



Pulp and Shipping Costs

Expecting short term increases FY21; looking to mitigate

Softwood (Radiata)


- FY20 low point in cycle; capacity high, lower demand
- FY21 pulp futures higher January 2021 on speculation of future demand from China

Hardwood (BEK)

- FY20 prices impacted by global oversupply
- FY21 futures higher driven by substitution of hardwood for softwood

Sea Freight

- FY21 pricing being driven by supply demand imbalance



Outlook

Sid Takla

CEO & Managing Director



FY21 – FY22 Outlook



FY21



FY22



Targeting 5-7%
revenue growth

- **Momentum** in feminine care, retail incontinence and B2B incontinence healthcare
- **H2 Recovery** in professional hygiene as COVID-19 impacts abate
- Part year **contribution** from TOM Organic

Targeting EBITDA
\$90-93m

- **Growth** in revenue and gross margin
- Earnings growth **moderated** by final year of absorption of stranded costs from exit of Australian consumer tissue and NZ baby businesses, along with rising pulp and sea freight prices

Targeting mid-single digit
revenue growth

- Continued **growth** across all core categories
- Second year **benefit** from TOM Organic

Targeting EBITDA
growth 10%+

- **Benefit** from abatement of stranded costs
- TOM Organic contribution including **synergies**

FY21 Phasing


Significant change in phasing due to COVID-19 impacts

1H FY20

- Retail benefited from COVID-19 panic buying
- COVID-19 related spike in demand in B2B channels
- Lower promotional and discounting activity during COVID-19
- Lower brand investment weighting 1H



EBITDA \$89.2m



2H FY20

- Lower retail volume as consumers “destocked” after panic buying
- COVID-19 lockdown measures impacted “away from home” demand
- Higher brand investment




1H FY21

- Lower volume due to panic buying in 1H20
- Increased promotional activity and discounting in retail channel
- COVID-19 impact on “away from home” demand
- Higher brand investment



EBITDA \$90-93m



2H FY21

- Return to higher levels of “away from home” activity as restrictions lift
- Growth in retail revenues via NPD launches; consumer de-stocking H2 FY20



Focus FY21 and beyond

Business reset complete, targeting sustainable growth and value creation



Reset now complete.
Well positioned for
long term value creation

- Exited **low margin, capital intensive** businesses
- Increased **investment** in core brands
- **Strong** and **flexible** balance sheet
- **Capacity** to fund future M&A



Company on a clear path
towards **sustainable**
future growth

- Sustainable, profitable **growth** initiatives
- Pipeline of product innovation
- Higher **growth**, higher **margin** categories
- Can **leverage** scale
- Continued brand **investment**



Essity Proposal



Essity Proposal To Acquire Asaleo Care

Recommended Transaction via Scheme of Arrangement



1

Asaleo Care and Essity announce that they have entered into a scheme implementation agreement which proposes Essity will acquire all outstanding ordinary shares in Asaleo, not already owned by Essity.

2

Total proposed value is \$1.45¹ per share, comprising \$1.40 cash per share in scheme consideration plus \$0.05 per share of permitted dividends (comprised of a \$0.03 ordinary and a \$0.02 special dividend per share). Franking credits attached to dividends are potentially worth an additional \$0.02 per share if fully franked.²

3

The independent non-Essity directors and the CEO and Managing Director⁴ unanimously recommend that shareholders vote in favour of the Scheme, in the absence of a Superior Proposal³ and subject to the independent expert's report concluding it is in the best interests of shareholders.

4

Shareholders do not need to act at the present time. A scheme booklet containing information relating to the Scheme, including the independent expert's report and details of the Scheme meeting, is expected to be sent to shareholders in late April 2021. Shareholders can vote at a Court-convened meeting, expected to be held first half June 2021.

¹ Subject to being a shareholder on the respective dividend record dates and the Asaleo Board determining, at its absolute discretion, payment of the special dividend.

² Asaleo expects that dividends will be fully franked, subject to a class ruling from the Australian Taxation Office.

³ Superior Proposal has the same meaning as given in the scheme implementation agreement.

⁴ CEO & Managing Director, Sid Takla. Refer to separate announcement today in relation to employment arrangements.

Essity Proposal To Acquire Asaleo Care

Transaction Highlights



The IBC believes the scheme is compelling for shareholders.



Independent Board Committee



Offer Premium¹

- **Total value to Asaleo shareholders \$1.45² representing an attractive premium of:**
 - 43.6% premium to the undisturbed closing price of \$1.01 on 9 December 2020;
 - 44.7% premium to the 1-month VWAP of \$1.00 to 9 December 2020;
 - 43.7% premium to the 3-month VWAP of \$1.01 to 9 December 2020; and
 - 43.5% premium to the 6-month VWAP of \$1.01 to 9 December 2020.



Certainty of Value

- 100% cash consideration provides shareholders with **certainty of value**.



Franking Benefit

- Franking credits attached to the dividends are potentially worth an **additional \$0.02** per share if fully franked (for shareholders able to realise the full benefit of franking credits)³.



No Financing or DD Conditions

- The Scheme is **not subject** to financing conditions or due diligence.

¹VWAPs are subject to rounding

²Comprising \$1.40 cash per ordinary share in scheme consideration, plus a \$0.03 per share ordinary dividend and a \$0.02 per share special dividend (subject to being a shareholder on the respective record dates and the Asaleo Board, at its absolute discretion, determining to pay the special dividend)

³Asaleo expects that dividends will be fully franked, subject to a class ruling from the Australian Taxation Office.

mal use only

